Acceleration of iron utilization after intravenous iron administration during activated erythropoiesis in hemodialysis patients: a randomized study

Ther Apher Dial. 2015 Apr;19(2):131-7. doi: 10.1111/1744-9987.12237. Epub 2014 Sep 26.

Abstract

This study aimed to evaluate the effect of different timings of iron administration during erythropoiesis activated by continuous erythropoietin receptor activator (CERA) on reticulocyte iron uptake in hemodialysis patients. In total, 110 patients were randomized to receive 40 mg intravenous elemental iron doses at all three hemodialysis sessions in the first week (IW1 group: n = 57) or in the third week (IW3 group: n = 53) after CERA administration. Following CERA administration at day 0, reticulocyte count increased, peaking at day 7. At days 7 and 14, the observed changes in Ret-He were higher in the IW1 group than in the IW3 group. Increases in total reticulocyte hemoglobin at day 7 were higher in the IW1 group than in the IW3 group. In contrast, there was only tendency toward greater total reticulocyte hemoglobin after iron administration in the third week in the IW3 group. Intravenous iron supplementation in the first week of CERA administration increases reticulocyte iron uptake; however, iron supplementation in the third week does not. The findings indicate that iron should be intravenously administered to increase the efficacy of CERA within 1 week of CERA administration during highly active erythropoiesis.

Keywords: Continuous erythropoietin receptor activator; Hemodialysis; Iron utilization; Renal anemia; Reticulocyte hemoglobin equivalent.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Administration, Intravenous
  • Aged
  • Erythropoiesis / drug effects*
  • Erythropoietin / administration & dosage
  • Erythropoietin / therapeutic use*
  • Female
  • Follow-Up Studies
  • Hematologic Tests
  • Humans
  • Iron / administration & dosage
  • Iron / metabolism*
  • Iron / therapeutic use*
  • Kidney Failure, Chronic / metabolism
  • Kidney Failure, Chronic / therapy*
  • Male
  • Polyethylene Glycols / administration & dosage
  • Polyethylene Glycols / therapeutic use*
  • Renal Dialysis*
  • Reticulocytes / drug effects
  • Reticulocytes / metabolism

Substances

  • continuous erythropoietin receptor activator
  • Erythropoietin
  • Polyethylene Glycols
  • Iron